Guided Lecture Notes, Chapter 37, Thyroid and Parathyroid Agents

Learning Objective 1: Explain the control of the synthesis and secretion of thyroid hormones and parathyroid hormones, applying this to alterations in the control process (e.g., using thyroid hormones to treat obesity, Paget disease, etc.).

 Provide an overview of the thyroid and parathyroid gland. (Refer to PowerPoint slide 2.)  Discuss the action of the thyroid gland. (Refer to PowerPoint slide 3.)  Discuss the thyroid control of hormone levels. (Refer to PowerPoint slide 4.)  Discuss the functions of thyroid hormone. (Refer to PowerPoint slide 5.)  Discuss how calcium is controlled in the body. (Refer to PowerPoint slide 6.)  Discuss the types of thyroid dysfunction. (Refer to PowerPoint slide 7.)  Discuss the causes of hypothyroidism. (Refer to PowerPoint slide 8.)  Provide an overview of hyperthyroidism. (Refer to PowerPoint slide 9.)  Provide an overview of parathyroid dysfunction. (Refer to PowerPoint slide 10.)  Provide an overview of Paget’s disease. (Refer to PowerPoint slide 13.)

Learning Objective 2: Describe the therapeutic actions, indications, pharmacokinetics, contraindications, most common adverse reactions, and important drug–drug interactions associated with thyroid and parathyroid agents.

 Provide an overview of the thyroid hormones available for replacement of thyroid hormone. (Refer to PowerPoint slide 14.)  Discuss the action, indication, pharmacokinetics, contraindications, cautions, adverse effects, and drug-to-drug interactions of thyroid hormone. (Refer to PowerPoint slide(s) 15 to 17.)  Discuss the action, indication, pharmacokinetics, contraindications, cautions, adverse effects, and drug-to-drug interactions of antithyroid agents. (Refer to PowerPoint slide(s) 18 to 20.)  Discuss the action, indication, pharmacokinetics, contraindications, cautions, adverse effects, and drug-to-drug interactions of iodine solutions. (Refer to PowerPoint slide(s) 23 and 24.)  Discuss the action, indication, pharmacokinetics, contraindications, cautions, adverse effects, and drug-to-drug interactions of antihypocalcemic agents. (Refer to PowerPoint slide(s) 25 and 26.)  Provide an overview of antihypercalcemic agents. (Refer to PowerPoint slide 27.)

Learning Objective 3: Discuss the use of thyroid and parathyroid drugs across the lifespan.

 Explain the use of thyroid and parathyroid drugs across the life span. (Refer to PowerPoint slide 28.)

Learning Objective 4: Compare and contrast thyroid and parathyroid prototype drugs with agents in their class.

 Discuss the thyroid hormone prototype drug Levothyroxin. (Refer to PowerPoint slide 29.)  Discuss the antithyroid agent prototype drug PTU. (Refer to PowerPoint slide 30.)  Discuss the iodine solutions prototype drug strong iodine products. (Refer to PowerPoint slide 31.)  Discuss the antihypocalcemic agents prototype drug Calcitriol. (Refer to PowerPoint slide 32.)  Discuss the antihypercalcemic agents - bisphosphonates prototype drug Alendronate. (Refer to PowerPoint slide 33.)  Discuss the antihypercalcemic agents - calcitonins prototype drugs Calcitonin. (Refer to PowerPoint slide 34.)

Learning Objective 5: Outline nursing considerations, including important teaching points, for patients receiving drugs used to affect thyroid or parathyroid function.

 Discuss the nursing considerations for patients receiving thyroid hormone. (Refer to PowerPoint slide 37 and Table on Nursing Considerations for Patients Receiving Thyroid Hormone.)  Discuss the nursing considerations for patients receiving antithyroid agents. (Refer to PowerPoint slide 38 and Table on Nursing Considerations for Patients Receiving Antithyroid Agents.)  Discuss the nursing considerations for patients receiving antihypocalcemic agents. (Refer to PowerPoint slide 39 and Table on Nursing Considerations for Patients Receiving Antihypocalcemic Agents.)  Discuss the nursing considerations for patients receiving antihypercalcemic agents. (Refer to PowerPoint slide 40 and Table on Nursing Considerations for Patients Receiving Antihypercalcemic Agents.)